{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"CR, Independent radiologist assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"}]}],"title":"PR, Independent radiologist assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"134"}]}],"title":"SD, Independent radiologist assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"66"}]}],"title":"PD, Independent radiologist assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"35"}]}],"title":"NE, Independent radiologist assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"CR, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"}]}],"title":"PR, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"138"}]}],"title":"SD, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"70"}]}],"title":"PD, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"15"}]}],"title":"NE, Investigator assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"Overall response is defined as the number of participants who had a complete response (CR) or a partial response (PR). According to RECIST, Version 1.0: CR, disappearance of all lesions; PR, a \\>=30% decrease in the sum of the longest dimensions (LD) of the target lesions (TLs) taking as a reference the baseline sum LD; Progressive disease (PD), a \\>=20% increase in the sum of the LD of TLs, or the appearance of \\>=1 new lesion; Stable Disease (SD), neither PR nor PD, persistence of \\>=1 non-TL. Participants with no follow-up radiological disease assessment were categorized as not evaluable (NE).","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the start of treatment until disease progression (assessed for an average of 10 months)","title":"Number of Participants in the Indicated Categories for Overall Response Assessed by an Independent Radiologist and the Investigator","type":"SECONDARY","unitOfMeasure":"participants"}